• Newsroom
  • Join us!
  • Newsletter
  • Kontakt
  • English English English en
  • Deutsch Deutsch German de
Experts Institut
  • Business Consulting
    • Business Solutions
      • Digitization
      • Sustainability Corporate strategy
      • Management systems
      • Project management
      • Strategy & Performance
      • Transformation & Leadership
  • GXP Consulting
    • GMP Beratung
      • Audits & inspections
      • GMP/GXP training courses
      • GMP Aircheck4
      • Continuous Manufacturing
  • Industries
    • Pharma
    • Service providers & trade
    • Automotive
    • FOOD & BEVERAGES
    • Financial service providers & insurances
    • Informationstechnik (IT)
    • Aerospace
  • Academy
    • Individuelle Inhouse-Schulungen
      • GMP/GXP training courses
    • Experts Institut Events
      • Academy
    • Direkt buchen
      • Live-Events
      • On-Demand Webinar
  • Kunden
  • Über uns
    • Über uns
      • Guideline
      • Portrait
      • Team
      • Geschäftsführung
      • Vision
      • Events
      • History Experts Institute
      • Sustainability at the Experts Institute
      • Social responsibility
    • Wissen
      • Newsroom
      • GMP Glossary
      • FAQ – Frequently asked questions in the GMP environment
      • Videos
    • Services
      • Retaxation
  • Search
  • Menu Menu
  • LinkedIn
  • Xing
GMP, GXP

Untrue Supplier-Audit Reports: The Danger of Ethnocentric GMP-Auditing

If You are in any QA / QU role and are responsible for audits and audit reports in the GxP-context, I encourage You to take time and read this, it will be worth Your while. And if You are a QP (like I have been), this is likely to help You.

Where We Pick Up the Audit Topic

Manufacturers of pharmaceutical products and marketing authorization holders are required to ensure that audits at critical suppliers and service providers are done in a regular basis: active substance suppliers, suppliers of primary and printed packaging materials, and many others. This is basic, everyone knows this. However…

The supply chain is typically globalized and suppliers and manufacturers of materials are located all over the globe. When audits are carried out at suppliers located in a different culture, auditors always bring in their understanding of GMP and quality expectations-and here is the news: these are projected by the auditors on the auditees in culturally driven way and interpretation.

Auditors are Biased and Lack Understanding

Often auditors are trained to ask clear questions, closed questions, sometimes intentionally open questions, hypothetical questions, and often “show me” questions. Auditors expect to hear clear cut answers, yes or no, black or white, clarity – ambiguity is not typically acceptable as an answer.

But this way of auditing and listening in audits is actually called #ethnocentrism and it leads to very inaccurate audit reports. Such inaccuracy is very dangerous for supply chain and product quality asusrance! And this is a danger this industry cannot affort. We don’t produce umbrellas, but medication, we do this for patients, people who have serious needs…

Auditors assume to be heard and understood like they would be in their own birth cultural context, and even in their own company. It is an expectation which auditors bring with them due to their cultural bias in how communication should work. And so they filter what they see and hear in an audit through what they believe everyone uses to communicate.

Another assumption is that because a standard like GMP is laid down in writing, everyone sort of will understand this the same way, or at least to a contained degree of variability. Another ehtnocentric assumption: keeping in with the text of GMP requirements is what drives quality. As long as everyone else shares this – no problem. But the issue is: not everyone does! As a matter of fact, most cultures in this world do not share the mindset that underlies GMP.

The underlying problem is that GMP and similar quality standards have spawned in a Western cultural framework. This framework is not the majority reality in the world, it is a minority view no matter how important we think we are. Auditors do in almost all cases not know this, and they do not understand how big the impact of this is on what is heard and understood in audits, and what documents and records really mean.

It is needless to say that many drug manufacturing companies care very little about this aspect of audits and audit reports. Since the auditee is perceived as a supplier and only as that, the auditors feel – just like their company – that treating audit situations as an exchange of two business partners is not necessary. Another proof of ethnocentrism.

Real Consequences – Supply Contraction and Patient Risk

Especially in Asia (supplier in China, India, Japan to name a few) this will ultimately lead to a contraction of the supply range, meaning that the supply to European and Western-based companies will be a decreasing market priority to these Asian suppliers. Suppliers in Asia are fine with the Asian market alone, we must not forget that. The West is a very small part of the global village community. If we don’t take this seriously then it is our own fault.

The much bigger issue for the now is though that audit reports most often misrepresent what is going on at the supplier. Miscommunication happens so often without the auditor(s) even noticing it. And it ends up in the audit report, either as a conclusion that a particular audit topic was fine at the supplier (though it wasn’t) or that observations and deficiencies are noted that are simply not true.

The issues that come with ethnocentric auditing, which happens in almost every cross-cultural audit are significant and relevant! And they are essentially unaddressed. Auditors should not be sent into such an audit setting without a proper understandig of this.

Now What?

We seek to train our consultants and audit specialists at EI and our client auditors regarding this issue. And although no person can be truly multicultural, knowing the pitfalls makes a world of difference for the quality that is delivered.

If You are an auditor You cannot guess things in another culture, even in a business or highly regulated setting. Someone needs to show You, teach You, make You understand, and apply it. If not then audit reports will be sub-standard, inaccurate at best. And we will convince ourselves erroneously that we did a good job, and we will deceive ourselves to think that we were the ones who taught the auditee something new, although it is us who had a chance to learn and we did not take it.

Do You want to be an auditor who after 30 or 40 years of work realizes “goodness I got this wrong all my life”? Patient health and safety depend more on accurate auditing than we might think. We owe it to those who depend on medication to do our vey best.

#auditsandinspections #thegoodauditor #interculturalcommunication #GMP #business #activesubstances #api #excipients #supplierqualification #supplychainmanagement

If You like to know more about this, feel free to contact d.gross@expertsinstitut.de or visit www.expertsinstitut.de.

9. January 2025/by Dr. rer. nat. Dietmar Gross
https://experts-institut.com/wp-content/uploads/2025/01/1732195742249.jpeg 720 1280 Dr. rer. nat. Dietmar Gross https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp Dr. rer. nat. Dietmar Gross2025-01-09 11:29:252025-01-09 11:31:56Untrue Supplier-Audit Reports: The Danger of Ethnocentric GMP-Auditing
GMP, GXP

Insights into our project experience: Successful implementation of quality assurance agreements (QAA) in the pharmaceutical industry

As part of a project for a pharmaceutical manufacturer and its contract manufacturer, we demonstrated our expertise in the implementation of quality assurance agreements (QAA). The aim of the project was to optimize the quality assurance processes and ensure compliance with the current GMP guidelines.
The project was implemented under challenging conditions, which were characterized by strict regulatory requirements and tight schedules. Our team of experienced GMP consultants and QA specialists developed tailor-made solutions, including the creation, review, updating and negotiation of quality assurance agreements, delimitation of responsibility agreements (VAV), technical agreements and QP agreements – in both German and English.
Close coordination with the client’s internal departments and external contractual partners was a key success factor. Thanks to targeted project management and precise negotiating skills, time-critical contracts were concluded on schedule. We also optimized relevant processes, revised SOPs and templates, thereby achieving significant efficiency gains.
Our expertise in supplier management and supplier qualification was crucial to the success of the project. In addition, we ensured sustainable implementation and compliance with regulatory requirements through targeted induction and training of the teams.
The successful implementation of the project not only led to a noticeable improvement in quality assurance, but also to a deepening of cooperation with the customers. This example illustrates how even complex challenges can be overcome with a clear strategy, sound expertise and a well-coordinated team.

4. December 2024/by Marina Weeger
https://experts-institut.com/wp-content/uploads/2024/12/Screenshot-2024-12-04-090331.png 432 769 Marina Weeger https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp Marina Weeger2024-12-04 08:59:252024-12-04 09:45:40Insights into our project experience: Successful implementation of quality assurance agreements (QAA) in the pharmaceutical industry
GMP

GMP standards for medicinal cannabis: guaranteeing quality in an emerging industry

The medical use of cannabis is gaining increasing recognition and legal approval worldwide, leading to growing demand and increased regulation. In this dynamic environment, Good Manufacturing Practice (GMP) standards are crucial for the production of safe, high-quality products. However, the implementation of GMP standards is a challenge for the medical cannabis industry, as many companies first need to establish the necessary structures and skills. Specialized consulting can make a significant contribution to the efficient implementation of GMP-compliant processes.

GMP standards and their importance in medical cannabis production

GMP standards, implemented by the Food and Drug Administration (FDA) and further developed by the World Health Organization (WHO) and adapted to the global market, are a global quality benchmark for the pharmaceutical industry. These standards require strict specifications for the documentation, control and monitoring of production processes in order to ensure product safety and efficacy [1]. In the medical cannabis industry, these standards are of fundamental importance, as there are no guidelines specifically developed for cannabis production, although cannabis products are also used as medicines and can affect vulnerable patient groups. Instead, reference is made to the general processing of herbal substances [2], which is particularly important in the drying and preparation of plants. GMP ensures that all products are manufactured in a hygienic environment under controlled conditions to avoid contamination and ensure the safety of the final products [3].

Challenges of GMP implementation in the cannabis industry

GMP implementation in cannabis production poses specific challenges. For example, ensuring consistent product quality requires precise control over the entire manufacturing process – from raw material extraction to bottling. Medical cannabis products must have consistent concentrations of active ingredients to ensure therapeutic effects, which requires precise process control and laboratory testing [4]. In many cases, however, companies lack comprehensive knowledge of GMP standards and their specific application to cannabis production.

GMP compliance is complex and requires not only the establishment of suitable processes, but also the training of personnel and the implementation of quality assurance systems. In addition, regulatory requirements vary from country to country and are constantly evolving. Strategic advice can help to overcome specific challenges and ensure ongoing compliance with GMP requirements.

Good manufacturing practice (GMP) in practice: important steps and measures

1. production environment and hygiene: GMP guidelines require a strictly controlled production environment to prevent contamination by microorganisms, heavy metals or pesticides. Cannabis products must not contain any undesirable residues that could impair efficacy or safety [5].

2. quality control and laboratory testing: Each production batch of medicinal cannabis must undergo rigorous testing to confirm the active ingredient content and rule out impurities. These laboratory tests ensure that the final product meets quality standards and that consumers are not exposed to any risks [3].

3. documentation and traceability: GMP compliance requires comprehensive documentation and complete traceability of products in order to be able to act quickly in the event of quality problems or recalls. Every production stage, every test and every release must be documented in detail in order to prove conformity [1].

4. staff training: GMP standards require continuous training and education of employees to ensure that all processes are carried out and documented correctly. For many companies in the cannabis industry, this poses an additional challenge, as specific GMP knowledge is often not sufficiently available in the team [4].

The added value of specialized consulting for GMP-compliant processes

Strict compliance with GMP standards is essential for companies in the medical cannabis industry in order to be successful on international markets and build trust with consumers. However, especially for companies that are new to the market, the implementation of these standards requires considerable organizational and financial effort.

Our consulting expertise supports you in all phases of GMP implementation – from the development of a customized quality management system to employee training and complete documentation. We also offer regular audits and support in preparing for inspections to ensure continuous GMP compliance.

Conclusion: GMP as a guarantee of safety and trust in the medical cannabis industry

The requirements for medical cannabis are constantly increasing, as patient safety is a top priority and regulatory requirements are growing. The implementation and maintenance of GMP standards are a basic requirement for any company that wants to establish itself in this market in the long term.

We are happy to support you in achieving GMP compliance cost-efficiently and sustainably, strengthening your market position and guaranteeing the safety of your products. Get ahead and in touch with us – info@expertsinstitut.de

Sources

1. Good Manufacturing Practices for Pharmaceutical Products: Main Principles. World Health Organization (WHO).

2. cannabis Q&A for the public

3. Quality Standards and Practices in the Medical Cannabis Industry. International Journal of Drug Policy.

4. WHO Guidelines on Good Agricultural and Collection Practices (GACP) for Medicinal Plants. WHO, 2003.

5. Good Distribution Practice for Medical Cannabis Products. European Commission, 2017.

Read our entire blog: https://experts-institut.de/newsroom/
And feel free to follow us on LinkedIn: https://de.linkedin.com/company/expertsinstitut

19. November 2024/by Philip Kenz
https://experts-institut.com/wp-content/uploads/2024/11/LinkedIn.png 1080 1920 Philip Kenz https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp Philip Kenz2024-11-19 16:04:222024-11-19 16:05:32GMP standards for medicinal cannabis: guaranteeing quality in an emerging industry
GMP, GXP

GxP audits: How important are they and how are they conducted?

In the highly regulated pharmaceutical industry, audits are more than just a control mechanism – they are an indispensable tool for ensuring the quality and compliance of processes. Audits play a key role in ensuring that companies adhere to the strict requirements of Good Manufacturing Practice (GMP) and other GxP standards. The aim is not only to identify errors, but also to continuously improve processes and eliminate weaknesses before they lead to errors or quality problems. The role of audits in quality management can therefore not be overestimated. They help to meet regulatory requirements and at the same time strengthen the trust of customers and authorities in the company.

Below you will find out what a GxP audit is, why it is so important for companies in regulated industries and how it can be carried out optimally.

What is a GxP audit?

An audit is a systematic, independent and documented review that serves to determine whether activities and results meet the planned requirements. So much for the theory.

In the GxP area, audits are particularly important in practice, as they ensure that all processes actually meet the strict requirements of GMP, GLP and GCP standards. These audits not only check compliance with regulations, but also whether processes are used for continuous improvement and risk reduction and actually make this contribution.

Why are audits in the GxP area so important?

Audits fulfill a central function in the so-called Pharmaceutical Quality System (PQS) and offer many advantages that are important for the entire industry:

  • Audits guarantee that companies comply with and implement the legal and regulatory requirements in such a way that the medicines produced are of truly impeccable quality and also safe.
  • Audits make it possible to identify potential errors in operations and production at an early stage so that measures can be taken to minimize risks. This prevents critical errors or weaknesses in the production process from leading to serious problems and questionable medicines from reaching the market and patients.
  • Audits offer the opportunity to evaluate existing processes and identify optimization potential. In this way, companies can increase their efficiency and improve quality at the same time.
  • Regular audits strengthen the trust of customers, partners and regulatory authorities. A well-documented and executed audit shows that the company is able to critically scrutinize itself in order to reliably deliver high-quality products to the market.

The audit process: step by step

An audit in the GxP area follows a structured procedure that enables the auditor to thoroughly examine the processes in the company. Typically, an audit consists of six main phases:

  1. Planning: Audit preparation is crucial for success. The parties involved must ensure that all relevant people and documents are available. Thorough planning ensures a smooth process.
  2. The initial meeting: In this step, the auditors and the representatives of the company to be audited meet at the start of the audit. The audit plan or the audit agenda is discussed again. Questions are also clarified here and expectations are defined if they have not already been clearly understood before the audit.
  3. Conducting the audit: The auditor checks the company’s premises, machines, documents and processes. Interviews with employees also take place during this phase in order to assess the practical implementation of the processes.
  4. The final meeting: At the end of the audit, the results are summarized. This is where we discuss what worked well and where there is room for improvement.
  5. The audit report: The auditor prepares a detailed report documenting the results of the audit. This report also contains recommendations to help the company eliminate weaknesses and further improve processes.
  6. Follow-up of the audit results: After the audit, follow-up is essential to ensure that the recommended measures have been implemented. This includes documenting the corrections and, if necessary, rechecks to ensure the sustainability of the improvements.

Preparing the audited company for a GxP audit: how to succeed

Thorough preparation is the key to a successful audit. Companies should ensure that their documents are complete and up-to-date and that their employees are aware of the requirements of the audit. Employee training plays a central role here, as a well-prepared team helps to ensure that the audit runs smoothly and possible deficiencies can be identified at an early stage.

Tips for audit preparation:

  • Review all important documents, including SOPs (standard operating procedures), batch documentation and qualification documents
  • If possible, carry out internal mock audits in advance to identify weaknesses in advance
  • Bring your team up to speed on regulatory requirements and audit expectations

Successful audit practice: the key to success

A successful audit requires careful preparation, a clear structure and detailed follow-up. Cooperation between the auditor and the audited company is of great importance in order to develop a common understanding of the requirements and expectations. This not only promotes compliance, but also the continuous improvement of processes. Companies that integrate regular audits into their business processes improve their quality assurance and reduce the risk of production errors or non-compliance with regulations.

Conclusion: Audits as the key to quality assurance

Audits are an indispensable part of quality management in the GxP sector. They not only help to ensure compliance with regulations, but also promote the quality and safety of products. Thorough preparation and the selection of experienced auditors are crucial to the success of an audit.

At Experts Institut, we not only offer training courses for auditors, but are also happy to support you in ensuring your compliance and continuously improving your processes. We can do “audits”. Contact us at info@expertsinstitut.de

Would you like to find out more?

Listen to our podcast episode “Audits in the pharmaceutical industry”, in which we examine the importance and challenges of audits in detail: https://podcasters.spotify.com/pod/show/experts-insights/episodes/Audits-in-der-Pharmaindustrie-e2of577

Read our blog: experts-institut.de/newsroom

Follow us on LinkedIn: Experts Institute LinkedIn

28. October 2024/by Dr. rer. nat. Dietmar Gross
https://experts-institut.com/wp-content/uploads/2024/10/LinkedIn-3.png 1080 1920 Dr. rer. nat. Dietmar Gross https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp Dr. rer. nat. Dietmar Gross2024-10-28 12:20:122024-10-29 09:55:18GxP audits: How important are they and how are they conducted?
GMP, News

GMP Guidance for Artificial Intelligence (AI), Machine Learning (ML) and Digital Transformation: How it Finally Begins to Enter the EU GMP Guide

The Now: Gaping Holes

When sifting through today’s status of the EU GMP Guide, it does not take an expert to see that there are gaping holes on topics of engineering, management of computerized systems, data integrity, digitalization and application of artificial intelligence.

Not that the guide has nothing to say to some of these areas. At least by means of implication the guide says lots of things between the lines. This very “in-between” is what gives pharmaceutical manufacturers quite a headache when facing governmental inspections.

The issue is that what it has to say does not cover what’s actually out there. And “by implication” is simply not a good advisor for the industry. It may be good enough for an inspector to set up interpretive requirements and for giving industry a hard time. But for a company it is simply not practicable when a text is elusive.

Although we have best practices like ISPE GAMP5 or other guidance somewhere out in the GxP universe, we would like to know from our most relevant guide-the EU GMP Guide-what is required. And this very guide has been doing a rather horrible job to provide the input industry needs (it seems not surprising that some EU countries struggle massively to keep life sciences and pharmaceuticals on their territory).

A New Hope

A new hope may be on the horizon as we have been expecting a revised version of Annex 11. There-so the concept paper tells us-we will receive a text that will address words such as artificial intelligence, clouds, and even digital transformation. One might wonder whether it is worth holding our breath for the release of the new Annex 11, as high hopes have been shown to greatly disappoint before. One might remember Annex 21 or interpretive documents from local supervizing authorities, that in the end have not been helpful for real life at all.

However, in this case it may be different. Can we guess some consequences from this next generation Annex 11?

GMP

GMP Data Integrity Finally Takes Center Stage

Although some would passionately disagree with me on this, the EU GMP guide has virtually lacked clarity on data integrity for decades. It was the US FDA who had to essentially teach us in Europe what Data Integrity is and why this is important. Without them we would still think that Good Documentation Practices and Validation of Spreadsheets is all it takes.

I love how every EU member state GMP inspector knows exactly what is necessary in terms of data integrity-only with next to no express textual basis for it in the EU GMP guide. I mean sure: evey company has by now heard of data integrity, letalone has received inspections that dealt with it. And yes, we were told after the fact that the GMP guide has “always meant” data integrity in various little phrases of the guide. But that seemed a bit of a crutch to assure the colleagues from US FDA that in Europe data integrity is something we “totally want and require!”

Point taken, it is true that in the Annex 11 we had such wording in some spots. And now the EU guide will finally take into consideration the fuller importance of data integrity-at least for computerized systems. One can tell that the EU grows more towards considering guidance from for example WHO or PIC/S.

The consequences will be that audit trails and audit trail review requirements will be clarified and likely deepend. More work. The bar for what is “basic” will be raised.

The same will happen for archiving, backups, and retrieval requirements for archived data. Companies will unlikely be able to keep playing the low-key game in the archiving area.

Management of Clouds will be a Topic

This will be upgraded, or actually decently considered in the new Annex 11. And here I must say that this is positive improvement. The GMP guide has been pretty much blind to this for quite some time now. It will be a reasonable change. It will be interesting to see how block-chain systems will be treated under the new Annex 11.

And I certainly will be interested to see how cloud hosts seriously validate and qualify their systems, software, and infrastructure. The hunsh is: this is going to cause trouble for some service providers. My recommendation to cloud providers who have pharma-clients: Get ready for it now, or You will be out of business before You know it.

If this enters Annex 11 it could mean:

– cloud services must qualify their infrastructure according to GMP.

– they must validate their software fully in line with GMP as well.

This essentially would require a quality-oriented quality management system (and no, ISO9001 would not suffice, not the slightest chance for anyone who wants to take this seriously).

GMP for Artificial Intelligence (AI) and Machine Learning (ML) will Hatch

We must be honest here: it might not be a whole lot of guidance what we will receive from the revised Annex 11:

The primary focus should be on the relevance, adequacy and integrity of the data used to test these models with, and on the results (metrics) from such testing, rather that on the process of selecting, training and optimizing the models.

https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/concept-paper-revision-annex-11-guidelines-good-manufacturing-practice-medicinal-products-computerised-systems_en.pdf

Though this quote from the concept paper is as elusive as sand running through one’s fingers, it does give us a tiny insight into what will be important to a regulator or a GMP-inspector: data (and their quality) used to feed AI models.

One of the biggest questions is: How in the world do we validate AI and ML? Will AI or ML need to be validated according to the typical V-model? In reality this seems almost impssible, since any software code change would required re-validation. And code changes might have to be expected, especially with machine learning. My assupmtion is that we will not receive much help here form the new Annex 11. Industry will be thrown back on non-governmental best practice guidance-as is often the case.

“No New Requirements”

It must be acknowledged that some of what we will find in the revised Annex 11 will likely be clarification and nailing down of requirements that were logical consequences from what is in the current version of the Annex. Yet, we will also find more work, new requirements.

For each company a careful gap assessment will be in order, and for those who have gotten away with mediocre management of electronic systems it will be time to act and invest in modernization.

Needless to say, that I am already looking forward to the next years at Experts Institut, when those projects will continue to fill our work schedules. It is a great challenge!

GMP Challenges for Small Pharmaceutical Businesses

I encourage representatives of small businesses – smaller pharmaceutical entities – to comment and to give feedback once the draft to the new Annex 11 is out. Often it is the larger pharmaceutical businesses that drive or influence what best practice is or what those texts may contain. A consequence can be that the requirements push smaller companies off the cliff of financial and infrastructural fesability. This does not need to be so. But small businesses must take a bit of a stand here. Take the chances You get, that is my recommendation. Digitalization and the use of AI and ML are unstoppable because neither society and nor the economy will not stop it. This is coming at the industry real fast. And it will likely make or break smaller business in the near future. So – get ahead with it!

Experts Institute can help!

Need help with GMP-Digitalization projects and AI-validation concepts? Contact us. Management consultancy GMP, GXP & Business Solutions | Experts Institut (experts-institut.com).

Read our full blog: https://experts-institut.de/newsroom/

And feel free to follow us on LinkedIn: https://de.linkedin.com/company/expertsinstitut

23. October 2024/by Dr. rer. nat. Dietmar Gross
https://experts-institut.com/wp-content/uploads/2024/10/blogbeitrag-1.jpg 349 918 Dr. rer. nat. Dietmar Gross https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp Dr. rer. nat. Dietmar Gross2024-10-23 11:29:122024-12-04 10:02:51GMP Guidance for Artificial Intelligence (AI), Machine Learning (ML) and Digital Transformation: How it Finally Begins to Enter the EU GMP Guide
GMP, GXP, News, Uncategorized

Quality Management Maturity: The Importance of Good English Writing Practices (GEWP)

English is common for most who work in a GxP-regulated industry. Though most would consider themselves firm English speakers, the truth of the matter is: most will never go beyond some standard vocabulary, and most have only little understanding of English grammar and writing style. After the Brexit, in Europe very few are English native speakers. One could likely make a case for that even English EU GxP Guidance and Drug Regulation documents suffer from this issue.

No, English is in fact not easy – good English is just not!

In company GxP documents and reports the English text often suffers from features of other languages which are unknowingly imposed on it because authors and reviewers are not native speakers.

Consequences of Poor Language Quality

Clarity and quality suffer, content is misrepresented, reports are harder to read later on, procedures are misinterpreted due to undetected ambiguity, even wrong conclusions can be the consequence of using substandard “EUnglish” instead of actual English. And when a native English speaking authority comes in for inspection (USFDA, TGA, MHRA) all of a sudden QA wonders why the authorities have such trouble seeing through the local QMS and GxP-system and find what they read rather irksome (if You need to look up “irksome” then I totally got You!). “And here we thought all is fine…”.

Tailored Training by Experts Institute

Experts Institut offers a customized and Taylor-made applicational training on “Technical Editing of GxP Documents: The Relevance of Quality and Style”. This training is relevant for really all levels of GMP-/GxP-regulated organizations. The training provides theoretical elements of English language features and how they can interfere with other languages in GxP documents and reports. Important elements in English writing style are presented as well. Application of the theoretical part is then trained in inductive workshop sections to gain immediate hands-on understanding of how all this plays out in real GxP life.

Basic quality systems can make good use of this, just as well established ones can. It is a great contribution to the foundation of Pharmaceutical Quality Management Maturity.

This training is one of many reasons why Experts Institut is so unique in its work portfolio: We go beyond GMP/GxP-only – We see the big picture – We see the whole. For your benefit.

Feel free to contact us and make an appointment to talk about how we can customize this expertise to Your need. Get ahead and in touch with us – info@expertsinstitut.de

Read our full blog: https://experts-institut.com/newsroom/

And feel free to follow us on LinkedIn: https://de.linkedin.com/company/expertsinstitut

22. August 2024/by Dr. rer. nat. Dietmar Gross
https://experts-institut.com/wp-content/uploads/2024/08/1724141485769.jpeg 837 1488 Dr. rer. nat. Dietmar Gross https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp Dr. rer. nat. Dietmar Gross2024-08-22 12:43:412024-10-29 07:59:20Quality Management Maturity: The Importance of Good English Writing Practices (GEWP)
GMP, GXP

Crossing Cultures in Audits and Inspections

Today the world, with its regulated industry, is strongly globalized. The cultural diversity of a company’s staff can be huge, reflecting different cultures from around the world. This is one reason why many would assume that the entire world can be talked to, related to, and understood quite readily. It is part of everyday work for many after all-or so we think.

In the area of audits and inspections, crossing cultures happens all the time. Different cultures bring different perspectives, which can influence how audits are perceived and conducted. Where supply chains are globalized, trans-national and trans-continental audits and inspections are mandatory and pretty much normal in many company and regulatory settings. Understanding the nuances of each culture involved is essential for effective communication and successful outcomes.

True Multiculturalism and Cultural Limits

This poses a problem though: we learn to communicate, read, and perceive in our birth culture. And even if a society is highly diverse, we are still product of a cultural framework that is discrete-in other words, that has boundaries. It is simply impossible for one person to really become multicultural-ourlifespan is just not large enough. You may be the child of a double or third culture set of parents, but true multiculturalism in a single individual is virtually impossible.

So as we are controlled by our birth culture, we do not learn how to properly navigate in foreign cultural contexts (and globalization does not do away with this at all). We may think we know what is going on around us when we engage people from other host cultures, but we really do not. Even in a seasoned friendship with someone from another country, there will still be a vast degree of ignorance in understanding the other person. We believe we know and understand. But we miss most of it in reality. We continue to filter everything we experience, see, hear and judge through what we believe is normal, and our frame of reference is our birth culture. And we cannot stop doing it because we are not even aware of it.

The Impact of Culture on Audits and Inspections

And now it gets interesting: This problem includes audit and inspection situations!
Good auditing is more than knowing compliance requirements, audit methodology, and a work experience of 100+ or even 1000+ audits.

Culture is so powerful that it controls everything we think, say and do. And what we expect of others. In an audit situation (also in GMP inspections), this routinely produces misunderstandings. And many of them are never corrected, simply because neither the auditor nor the auditee is aware of them.

From document reviews, an auditor may conclude that a company is falsifying records, when the truth is though that what the auditor saw has nothing to do with cheating at all.

An auditor may think the auditee is trying to avoid saying the truth about a given audit question or subject, but there is no intent of this in the conversation at all. But the auditor is blind to this.

As a result of examples like these, auditors will put their impressions into the report, in a coded form of course, but it will color all parts of the report and the perception of GMP deficiencies-even the judgment on severeness.

If an auditor is not aware of what is missed and where the personal perception of things is going astray, then such an auditor must improve. The objectiveness of the report will suffer, and the picture that is brought home is greatly inaccurate. We do a disservice to the auditee and to our own sending unit. And frankly, to ourselves…

This plays out even more drastically in audits of suppliers or service providers where no GMP or GxP quality system is available. Such cultural ignorance can make or break the business relationship altogether.

How can you improve?

  • Stop thinking that cultural differences are easy to figure out. You cannot guess them. You need extra training for this.
  • Understand that cultural differences have little to do with differing food preferences or how a business card must be presented.
  • Respect that standards-even GMP-can be lived effectively in different ways.
  • Open to the truth that you do not know everything best.

Read our full blog: https://experts-institut.de/newsroom/

And feel free to follow us on LinkedIn: https://de.linkedin.com/company/expertsinstitut

1. August 2024/by Dr. rer. nat. Dietmar Gross
https://experts-institut.com/wp-content/uploads/2024/07/1721830906970.jpeg 720 1280 Dr. rer. nat. Dietmar Gross https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp Dr. rer. nat. Dietmar Gross2024-08-01 09:38:532024-10-09 15:28:40Crossing Cultures in Audits and Inspections
GMP, GXP

Computerized systems (CS)

CS are becoming increasingly important, especially in the pharmaceutical industry, in order to meet the increasing demands on production. At the same time, their use must not compromise patient safety.

This brings with it increasing challenges in the scope of validation and qualification of the system: Proof that CS function properly and do not pose an increased risk to patients can only be provided by taking a holistic view of the system. A master plan is therefore a useful document for defining the scope of the project.

Complexity of the scope of validation

The initial classification of the CS into a software category according to GAMP 5 provides guidance on the complexity of the scope of validation:

  1. Operating systems
  1. N/A
  1. Non-configurable software (standard software)
  1. Configurable software
  1. Individual customer software

A risk assessment is now used to check the criticality of the CS with regard to GxP relevance, i.e. the extent to which there is an impact on patient safety. A detailed identification and analysis of risks and the definition of suitable control measures to minimize or completely exclude these risks is essential. A continuous review is also essential for a complete audit.

In addition to determining areas of application, exact specifications and their influence on patient safety, individually planned tests with suitable acceptance criteria are also included in the CS review.

The validation of the process then goes hand in hand with the qualification of the process environment, divided into the phases of design, installation, function and performance testing. This allows individual specifications to be checked and verified step by step.

Only once qualification and validation have been successfully completed and proof of suitability for the intended process has been provided can the CS be used without any increased risk to patient safety.

Read our entire blog: https://experts-institut.de/newsroom/

And feel free to follow us on LinkedIn: https://de.linkedin.com/company/expertsinstitut

2. May 2024/by Dr. rer. nat. Dietmar Gross
https://experts-institut.com/wp-content/uploads/2024/05/CS_Artikel_Philip_Kenz.jpg 1080 1920 Dr. rer. nat. Dietmar Gross https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp Dr. rer. nat. Dietmar Gross2024-05-02 08:47:462024-10-09 15:33:17Computerized systems (CS)
GMP, GXP

Supplier qualification for pharmaceutical manufacturers

Field report by an EI consultant from a supplier qualification project for pharmaceutical manufacturers

In the period from 2019 to 2022, I was involved in a project for the supplier qualification of drug manufacturers and active ingredient manufacturers at a pharmaceutical company and generics manufacturer. The project team, consisting of up to four colleagues, was entrusted with various tasks and focal points to ensure smooth implementation.

Project overview and responsibilities

Before I took over the management of this project, my colleagues had already developed a checklist for the review of audit and inspection reports. As project coordinator, my main responsibility was to manage, coordinate and plan the activities. My tasks included direct customer contact and the exchange of information as well as requesting and evaluating audit reports for supplier qualification. I was also responsible for the creation and versioning of technical agreements, supplier monitoring and internal coordination with the specialist departments.

Inspection reports and quality assurance in supplier qualification

One of my main tasks was to check and evaluate the inspection reports (audit reports) for content, accuracy and completeness in accordance with the applicable GMP guidelines for the products and to document this using internal guidelines (SOPs) and checklists (audit report review).

Challenges

The challenges in this project were manifold. A tight schedule due to upcoming production & product releases required the tasks to be completed on time. In addition, global customer contact required effective communication and coordination across European borders. Another challenge was to work through the previous year’s backlog while maintaining ongoing business, particularly due to staff shortages and changes in the team. After completion of the project at the customer’s site, it was important to transfer the newly acquired knowledge and processes to the resident and newly hired staff and to ensure that the quality assurance processes & measures are continuously implemented and adhered to.

Successes and results of supplier qualification

Despite the challenges, the long-term collaboration within the team was very successful and our structured approach enabled us to fully meet the client’s requirements. Our work contributed significantly to the quality assurance of the company’s medicines and ensured that suppliers met the required quality standards.

Contact and support for supplier qualification

Are you also looking for support in supplier qualification or quality management? Our experienced team is ready to make your project a success. Contact us for a customized solution that is precisely tailored to your needs. Get ahead and in touch with us – info@expertsinstitut.de

Read our entire blog: https://experts-institut.de/newsroom/

And feel free to follow us on LinkedIn: https://de.linkedin.com/company/expertsinstitut

4. April 2024/0 Comments/by ExpertsInstitut
https://experts-institut.com/wp-content/uploads/2024/04/Bild-Blog-Marina.png 1080 1920 ExpertsInstitut https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp ExpertsInstitut2024-04-04 08:30:352024-10-09 15:40:37Supplier qualification for pharmaceutical manufacturers
GMP, GXP, News

GMP and Digitalization: Some basic thoughts

It is almost 8.00 am, we are standing on front of a building which houses an officially GMP-accredited contract laboratory service. Our task for today: carry out a full blown GMP-audit on the contract lab.

On the inside I am a bit excited. Because I know that in each audit I do not only evaluate others, but I will also gain and learn! And each auditee – be it a laboratory, a GMP-manufacturer or a material supplier (API, excipients, packaging materials) is different, and each uses different ways and systems to implement GMP. So far so good.

Later that day the audit is over and my co-auditor and I we feel overall happy with the audit. Still – we also feel disillusioned: we had expected a more modern way of raw data, data and document management. What did we find? An almost 100% paper-based GMP- and data management system, with all its nicks and dents when it comes to the GMP such a system can provide – it is alright, but it no doubt has limits.

Fully paper-based – that something like this still exists? And that in a GMP-bound establishment? It sure does still exist.

In the GMP-Universe the Digitization Truck has departed, but by far not delivered to all yet!

In our line of work at Experts Institut, we are often surprised by how many companies in the drug manufacturing, medical device, and cosmetic GMP areas operate with a very low degree of digitalization in their processes and data management. This observation grounds everyone and reminds us that digitization is not as advanced in the regulated industry as we might like to believe. Despite being a socio-economic and political desire among regulators and industry, progress is still lacking. In fact though, it is not(!) a given, it is not a self-propagating realization all over the place. And this does not only concern small companies who seem to just not be able to finance the digital transformation. It also concerns for example medium-size GxP-entities. If You think that the size of a company is an indicator for its degree of digitalization then You need to think again. There is no such connection. You’d be surprised what we encounter in our daily work.

Even politics, cultural Western optimism and the strong drive to achieve and constantly change towards something new is not always the recipe for producing a digital revolution by and large.

Incentives for change must come from the market, it must be attractive, plausible to implement and at reasonable cost. And in a highly regulated area like the white industry(Pharmaceutical GMP, Medical Device Quality Assurance, Cosmetic-Industry) New means not only Opportunity, but also Risk. And in white industry products the risk is considerable. An excellent example is the timidity of the GxP-industry to enter continuous manufacturing transformation – for a lack of experience with the regulators in this area. A similar reason may be at the root of the spotty coverage of digitalization.

Concerns and Opportunities of Digitalization for GxP Establishments

Some companies shy away from larger transformations due to finances thin-stretched. And due to a blurred understanding where then the actual benefit of digital data- and process-management really hit home positively.

Others simply do not see any need to change and keep up with modernization. Because for a period of time resisting change can go without noticing any consequences in the business numbers and balances. Even in terms of basic GMP-systems quite a few companies are chronically underfinanced.

Again others are apprehensive about the risk that may come to their data and company information due to migrating everything into electronic formats, networks and clouds – and that is a very understandable risk. There are solutions to protect data from even the most sphisticated attacks, but they will cost.

Looking at the opportunities: once digitalization has reached a company’s operational processes – where product is actually made (not just where warehousing and document management are electronic) – a company has arrived on a temporary plateau of readiness for tomorrow.

And here is the thing: that readiness will likely make or break any business eventually – but most certainly a GMP-business!

You will need digitalized company processes (manufacturing, analytics, logistics, quality management, compliance, engineering and technical systems) and data management to be ready for:

  • a globalized approach in making business wich data, knowledge and information sharing at the top (regulatory submission, block chain approaches for decentralized data management),
  • adapting to constantly advancing regulatory standards for GMP-data management and managing modern technologies in development and even in routine production (see for examples EU GMP Guide Annex 1),
  • the time when advanced and continuous manufacturing becomes more and more established (and this is already happening),
  • advancing cost efficiency concerning staff Your system would otherwise require to cater to the massive burden of GMP-/GxP-requirements.

Where to start? And how to get on the truck?

Digitalization in a GMP-/ GxP-liable company typically follows some sort of evolutionary model.

  1. Basic for any company is to have at least material management systems, warehousing and logistics managed by electronic systems. At least for article data and inventory as well as location and status management such systems are standard. This is nothing new of course. But I tell You: there are in fact some companies that don’t even have that.
  2. The second layer is often electronic Document Management (eDMS).
  3. Then comes electronic batch record – at least partially, more often electronic deviation and change management or other QM subsystems – mostly non-integrated but separate applications.
  4. and then – typically – a full electronic Quality Management System, some commpanies using the opportunitydigitizing their business and administrative processes if they haven’t so yet.
  5. Global companies need to deal with additional issues with data sharing and data security across the corporation, leading to for example decentralized data storage solutions for example controlled via block chain technology.
  6. And by the latest at that point comes the phase of trying to integrate all of this.
Basic Evolutionary Degress of Digitalization in GMP and GxP-liable Companies (pharmaceutical manufacturing and on-coming suppliers, medical devices industry, cosmetics).

As You can see: if Your company is currently a low-digitized business – do not be dismayed. You may have just about missed out all those years where all the others have hustled and bustled to add one little digital island system after the other. And You now have the advantage to look back on this and make a decision to roll out digitalization compreheneively and for the first time!

Digitalization in a GMP-Environment

There are challenges of course. Digitalization cannot be rushed or it will result in a gigantic failure with data loss, loss of company spirit and – worst case – of good people who will quit over the frustration of the failed digitalization effort. Leadership will lose credibility and trust – which is worse than anything from a company perspective.

The more integrated You advance Your digitalization the more keeping in with the validated state is a true GMP-challenge. And a huge caveat I must place here is: Be very thorough when working with validation-packages from software suppliers! They come from a non-GMP quality system environment. Often no QMS around the software development at all. And so You need to take charge of what is done concerning validation (initial, updates, integration and post-integration management) – even and especially when it is an ISPE GAMP®5 category 3 or category 4 system. And do not mistake brand names for assurance of GMP-compliance. Our audit practice shows that even systems which are heavily advertized for can lack basic regulatory compliance requirements or are not fully compatible with local national GxP-requirements. (An issue that even electronic deviation workflows or eBR systems can have).

For some newer technologies (Blockchain Technology, Decentralized Data Management, AI / Machine Learning / Neuronal Networks) You must understand: regulatory agencies are yet to say and to judge what they require from the GxP-viewpoint, depending on each situation of digital integrated process landscaping and data generation and management. Of course You can apply the current GxP-regulations’ point to now. But it may not in all cases be what You need.

And take a good look where You will market Your products: some regulatory agencies are on high alert concerning data and processes in digitalized environments and close to publishing guidance, others are – yet – fast asleep but won’t be forever.

What We (EI) do when We support a company in digitalization or digital transformation?

We Support Your planning – Organization and Required Efforts:

  • Feasibility study, digitalization concept, regularoy GMP-/GxP- and cGMP compliance assessment, also of existing levels of digitalization.

EI prepares Your body of documents:

  • With You we estalish and review the required GxP-relevant document You will need for individual systems and for global structure concept papers and policies keeping in with Your data integrity and data security requirements.

We work with those from Your company who will live and operate the / in the system:

  • Coordinating a digitalization project can be challenging and requires a sober and coordinative mind and management skills. Often companies new in the arena of digitalization do not have personnel to carry such a project and coordinate all the stakeholders – on top of their daily workload. But we (EI) have people who can take such a mandate and help Your own people advance in knowledge and with the project alike.
  • We keep alliance with partners who can drive the actual digitalization of data. Especially if you find no suitable business counterpart for example doing power BI for data pooling structures and more.

What will it take Your company (with or without external help)?

If You do digitalization – especially if You take a larger step (no matter in what area in Your GMP-, GDP, or GxP-company), You might as well do it wholeheartedly.

  • It will take extra effort on the part of everyone involved, and this is a real extra – not just an imaginary thought. Prepare Your staff wisely! Communicate with credibility where this is going.
  • It will take a darn good project manager and project management structure that can react to the unforeseen.
  • It will take nerve – lots of nerve – to face how many things that used to be non-digitalized actually never really worked! This will cause delay.
  • It will take plausible timelines that are only to a limited degree tied to immediate business goals – for then if it (digitalization) delays or fails – then all fails!
  • And – most importantly – it will take a change agent to generate acceptance of the things that are coming.

All things considered: be courageous and give it a go. In the long run there will likely be no way around a rather comprehensive digitalization for GxP-companies. Now is a good time.

Get ahead and in touch with us – info@expertsinstitut.de

Read our full blog: https://experts-institut.de/newsroom/

And feel free to follow us on LinkedIn: https://de.linkedin.com/company/expertsinstitut

28. March 2024/by Dr. rer. nat. Dietmar Gross
https://experts-institut.com/wp-content/uploads/2024/03/1711610066872.png 720 1280 Dr. rer. nat. Dietmar Gross https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp Dr. rer. nat. Dietmar Gross2024-03-28 18:34:562024-10-29 07:59:27GMP and Digitalization: Some basic thoughts
Page 1 of 212
Recent
  • Deviation Management
    Enhancing Process Stability through Effective Deviation...2 months 
  • Supplier-Audit Reports
    Untrue Supplier-Audit Reports: The Danger of Ethnocentric...9. January 2025 - 11:29
  • Qualitätssicherungsvereinbarungen
    Insights into our project experience: Successful implementation...4. December 2024 - 8:59
  • Test4. December 2024 - 8:57
Popular
  • Retaxation
    Retaxation – a lucrative instrument for health insurance...16. July 2024 - 9:12
  • Cultures in Audits & Inspections
    Crossing Cultures in Audits and Inspections30. July 2024 - 9:14
  • Cultures in Audits & Inspections
    Crossing Cultures in Audits and Inspections1. August 2024 - 9:38
  • English
    Quality Management Maturity: The Importance of Good English...22. August 2024 - 12:43

Tags

AI AI Annex Annex 11 Application Artificial Intelligence Audit audits Cannabis Certification Clean room Computerized systems Cultures Curriculum vitae Cytostatics Data Integrity Draft Germ count Germ count monitoring GMP GXP Health insurance Information security inspections ISO 27001 ISO standard Laboratory Machine Learning NIS-2 Personnel consulting Pharmacy Reagents Regulations Retaxation Sustainability Transformation

Kategorien

  • Business Solutions
  • GMP
  • GXP
  • News
  • Personnel consulting
  • Retaxation
  • Sustainability
  • Uncategorized

Archiv

  • March 2025 (1)
  • January 2025 (1)
  • December 2024 (2)
  • November 2024 (2)
  • October 2024 (3)
  • September 2024 (3)
  • August 2024 (2)
  • July 2024 (2)
  • May 2024 (1)
  • April 2024 (2)
  • March 2024 (2)
  • February 2023 (10)

Neustadt

Experts Institut Beratungs GmbH
Kirchwiesenstrasse 5

D-67434 Neustadt a. d. Weinstraße

Phone: +49 (0)6321 969210
E-mail: info@expertsinstitut.de

Fax: +49 (0)6321 9692199

Bamberg

Experts Institut Beratungs GmbH
Untere Sandstraße 53

D-96047 Bamberg

Phone: +49 (0)951 51939330
E-mail: info@expertsinstitut.de

Freiburg

Experts Institut Beratungs GmbH
Habsburgerstrasse 101a

D-79104 Freiburg im Breisgau

Phone: +49 (0)6321 9692120
E-mail: info@expertsinstitut.de

St. Gilgen (Austria)

Experts Institut Beratungs GmbH
Helenenstrasse 16

A-5340 St. Gilgen, Austria

Tel.: +43 (0)6227 21068
E-mail: info@expertsinstitut.de

kununu
  • Link to LinkedIn
  • Link to Xing

© 2024 Experts Institut Beratungs GmbH
  • Imprint
  • Data protection
  • AGBs
  • Cookie Directive (EU)
Scroll to top